The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
The current coronavirus disease 2019 (COVID-19) pandemic is the first to apply whole-
genome sequencing near to real time, with over 2 million severe acute respiratory syndrome …
genome sequencing near to real time, with over 2 million severe acute respiratory syndrome …
[HTML][HTML] Omicron variant (B. 1.1. 529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
M Dhawan, ARA Saied, S Mitra, FA Alhumaydhi… - Biomedicine & …, 2022 - Elsevier
Since the start of the COVID-19 pandemic, numerous variants of SARS-CoV-2 have been
reported worldwide. The advent of variants of concern (VOCs) raises severe concerns amid …
reported worldwide. The advent of variants of concern (VOCs) raises severe concerns amid …
Global landscape of SARS-CoV-2 genomic surveillance and data sharing
Genomic surveillance has shaped our understanding of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) variants. We performed a global landscape analysis on SARS …
coronavirus 2 (SARS-CoV-2) variants. We performed a global landscape analysis on SARS …
Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants
Abstract The coronavirus disease 2019 (COVID-19) pandemic has demonstrated a clear
need for high-throughput, multiplexed and sensitive assays for detecting severe acute …
need for high-throughput, multiplexed and sensitive assays for detecting severe acute …
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
The emergence of SARS-CoV-2 variants with mutations in major neutralizing antibody-
binding sites can affect humoral immunity induced by infection or vaccination,,,,–. Here we …
binding sites can affect humoral immunity induced by infection or vaccination,,,,–. Here we …
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
AC Medeiros-Ribeiro, NE Aikawa, CGS Saad… - Nature medicine, 2021 - nature.com
CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in
several countries. However, its immunogenicity in immunocompromised individuals has not …
several countries. However, its immunogenicity in immunocompromised individuals has not …
Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants
J Arizti-Sanz, AD Bradley, YB Zhang… - Nature biomedical …, 2022 - nature.com
The widespread transmission and evolution of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) call for rapid nucleic acid diagnostics that are easy to use …
coronavirus 2 (SARS-CoV-2) call for rapid nucleic acid diagnostics that are easy to use …
Comparative transmissibility of SARS-CoV-2 variants delta and alpha in New England, USA
R Earnest, R Uddin, N Matluk, N Renzette… - Cell Reports …, 2022 - cell.com
Summary The SARS-CoV-2 Delta variant rose to dominance in mid-2021, likely propelled by
an estimated 40%–80% increased transmissibility over Alpha. To investigate if this …
an estimated 40%–80% increased transmissibility over Alpha. To investigate if this …
Evolutionary trajectory of SARS-CoV-2 and emerging variants
The emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), and more recently, the independent evolution of multiple SARS-CoV-2 …
(SARS-CoV-2), and more recently, the independent evolution of multiple SARS-CoV-2 …
Two years into the COVID-19 pandemic: lessons learned
SJR da Silva, JCF do Nascimento… - ACS infectious …, 2022 - ACS Publications
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …